MedTrace Logo

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

NCT00186394 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2010-07-27

No results posted yet for this study

Summary

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

Conditions

  • Lymphoma, Non-Hodgkin
  • Blood and Marrow Transplant (BMT)
  • Lymphomas: Non-Hodgkin

Interventions

PROCEDURE

ablative allogeneic hematopoietic cell transplantation

Sponsors & Collaborators

Principal Investigators

  • Wen-Kai Weng · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
61 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186394 on ClinicalTrials.gov